Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

This study has been completed.
Information provided by (Responsible Party):
Martin Burian, Medical University of Vienna Identifier:
First received: March 9, 2011
Last updated: August 8, 2013
Last verified: August 2013
In a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in patients suffering from Hereditary Haemorrhagic Telangiectasia together with KTP Laser therapy. The aim of this study is to evaluate the effectiveness of submucosal intranasal bevacizumab compared to placebo in a randomized double blind trial setting.

Condition Intervention Phase
Morbus Osler
Drug: Bevacizumab
Drug: NaCl
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • relative change in average daily Epistaxis VAS scores compared to baseline [ Time Frame: day 10 - 84 posttreatment ]
    Daily epistaxis VAS scores are recorded in a diary. The baseline score is the average daily epistaxis VAS score 4 weeks before treatment (day -28 to 0). This score is compared to the average daily VAS score day 10-84 posttreatment. The relative change of this average score compared to baseline is the primary outcome.

Secondary Outcome Measures:
  • Epistaxis Severity Score HHT-ESS compared to baseline [ Time Frame: 3 months post treatment ]
  • Epistaxis frequency, duration and severity compared to baseline [ Time Frame: day 10 - 84 posttreatment ]
  • Number of emergency department visits due to epistaxis compared to baseline [ Time Frame: day 10 - 84 posttreatment ]
  • lab results (ferritin values, Hb, Hct) compared to baseline [ Time Frame: day 84 posttreatment ]
  • Number of transfusions needed compared to baseline [ Time Frame: day 10-84 posttreatment ]
  • Average daily epistaxis VAS scores compared to baseline among age groups and among groups with different epistaxis severity [ Time Frame: day 10-84 posttreatment ]

Enrollment: 15
Study Start Date: March 2011
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bevacizumab
submucosal intranasal bevacizumab on day 0
Drug: Bevacizumab
100mg intranasal submucosal bevacizumab in 10ml
Placebo Comparator: placebo
0.9% NaCl intranasal submucosal on day 0
Drug: NaCl
10ml of 0.9% NaCl intranasal submucosal


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed and staged HHT (Shovlin et al 2000)
  • Age 18-80
  • Minimum of 2 episodes of epistaxis/ week
  • Ability and willingness to complete diary and comply with study requirements.

Exclusion Criteria:

  • Uncontrolled hypertension (systolic blood pressure > 150mmHg, diastolic blood pressure > 90mmHg)
  • History of a thromboembolic event, including myocardial infarction or cerebral vascular accident
  • Malignancy of the upper respiratory tract within the last year
  • Recent (<3 months) or planned surgery
  • Proteinuria
  • Nasal intervention (Laser or Cautery) in pretreatment phase
  • Allergy to local anesthetic
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01314274

Universitätsklinik für HNO, Medizinische Univeristät Wien
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Martin Burian, Prof. Dr. Martin Burian, Medical University of Vienna Identifier: NCT01314274     History of Changes
Other Study ID Numbers: bevacizumab HHT
2009-018049-19 ( EudraCT Number )
Study First Received: March 9, 2011
Last Updated: August 8, 2013

Keywords provided by Medical University of Vienna:
Hereditary haemorrhagic telangiectasia

Additional relevant MeSH terms:
Telangiectasia, Hereditary Hemorrhagic
Vascular Diseases
Cardiovascular Diseases
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Pathologic Processes
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on April 21, 2017